Hopp til innhold

Selected items added to basket

Go to basket

Availability of essential NCD medicines and basic technologies (Indicator 19)

Published


The indicator describes the following: Availability of essential NCD medicines, including basic technologies in both public and private facilities.


Have you found an error?

This indicator is part of Target (9): Essential medicines and basic technologies for the treatment of serious NCDs. 

The following medicines and types of medication are considered to be NCD medicines: Acetylsalicylic acid; ACE inhibitors; thiazides; long-acting calcium channel blockers; metformin; insulin; bronchodilators; steroid inhalants. 

The following equipment are considered NCD technologies: Blood pressure measurement device; a weighing scale; blood sugar and blood cholesterol measurement devices; urine strips for albumin assay. 

Results

In Norway, access to NCD medicines and technologies is close to 100 per cent. 

With the exception of insulin, there is generic competition in all types of NCD medication. According to the Norwegian Medicines Agency’s shortage review, there have been no significant shortages of the medicines stated above. To safeguard access to insulin in Norway, pharmaceutical wholesalers supplying medicines to pharmacies in Norway are required to maintain additional stocks equivalent to two months of insulin sales. 

Data source: Norwegian Medicines Agency’s shortage review

The data source for this indicator is the Norwegian Medicines Agency’s shortage review 

Effect measure

  • Availability of NCD medicines and technologies 

Global indicator definition

Indicator 19. Availability and affordability of quality, safe and efficacious essential NCD medicines, including generics, and basic technologies in both public and private facilities.

Authors and contacts

Text compiled by the Department of nutrition, prevention and public health, Public Health Division, the Norwegian Directorate of Health in collaboration with the Department of Non-communicable Diseases at the Norwegian Institute of Public Health.